These drugs can be wonderful, but they each have many side effects.

Is the patient's blood count okay. Dosing for requip ropinirole hcl ; tablets for moderate-to-severe and efavirenz.

Order Ropinirole We have also commenced formulation work on two new product candidates, tizanidine oral spray and ropinirole oral spray. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. In addition, companies may be unable to enroll patients quickly enough to meet expectations for completing clinical trials. The timing and completion of current and planned clinical trials of our product candidates depend on, among other factors, the rate at which patients are enrolled, which is a function of many factors, including: the number of clinical sites; the size of the patient population; the proximity of patients to the clinical sites; the eligibility criteria for the study; the existence of competing clinical trials; and the existence of alternative available products. It makes me wonder about the relationship of migraines to seizure disorders and carbidopa. Authoritative body National Institute of Health. Herbs and Supplements Dandelion Taraxacum officinale ; Monographs ESCOP Monographs. 2003, 2nd Edition; p502-3 root ; . UMM. Herb-monograph Dandelion Taraxacum officinale. Monograph. Alt Med Rev 1999; 4 2 ; : 112-4. Textbooks Bisset NG. Herbal drugs and Phytopharmaceuticals. Medpharm Scientific Publishers, Stuttgart. 1994; p486. British Herbal Pharmacopoeia. 1996; p68-9.

Cheap Ropinirole Latin: Grifola frondosa Japanese: Mushikusa English: Hen-of-the-Woods WHAT IT DOES: Maitake Mushroom is sweet in taste and neutral in energy. It is a nourishing adaptogenic tonic that helps nourish the immune system and identify, target and destroy invaders, including cancer cells. RATING: Gold SAFETY ISSUES: None known STARTING DOSAGE: Fresh mushroom: one-half cup cooked, two to three times per week Dried fruiting body capsules: two 500-mg capsules two to three times per day. Extract tincture one gram mushroom 30 drops ; : 15-30 drops two to three times per day Proprietary D-fraction liquid: five to 25 drops two times per day. Maitake mushrooms are a wonderful food tonic, illustrating Nature's ability to harness her magic. They have been harvested in Eastern North America for years and sold to restaurants as a delicacy. The Japanese retrieve them from the mountains of Northeast Japan. Now that they are becoming available commercially as foods, make sure to include them in your diet. When eaten whole, they tonify the body, increase energy, keep the immune system healthy, and increase longevity. We use maitake extracts as a staple in our treatment of immune-compromised cancer patients. The extracts contain high levels of beta-glucan, a well-researched immune system activating agent. Research highlights Extracts from maitake show anti-tumor action by directly activating various immune system components, including macrophages, complement, cytokines, natural killer NK ; cells, and tumor necrosis factor Borchers et al., 1999; Nanba et al., 1997; Kurashige et al., 1997 ; . Beta-glucan seems to override the normal resistance of tumor cells to the cytotoxic activation of phagocytes and NK cells. This allows the complement part of the immune system to function against tumor cells in the same way that it normally functions against bacteria and yeast Kubo et al., 1999 ; . Maitake mushroom has demonstrated an ability to alter fat metabolism in animal studies by inhibiting both the accumulation of liver lipids and the elevation of serum lipids Kubo et al., 1996 ; . The fruiting body of maitake was confirmed to contain substances that exhibit antidiabetic activity, as illustrated by its ability to lower blood glucose levels Kubo et al., 1994 and levodopa. Concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000; 18: 3384 Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001; 7: 2246 Martenson JA, Vigliotti AP, Pitot HC, et al. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003; 55: 130510. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 51: 12819. Van Putten JW, Price A, Van Der Leest AH, Gregor A, Little FA, Groen HJ. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003; 9: 24727. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy. Ropinirole tablet Ported by a greater proportion of ropinirole-treated patients compared with placebo-treated patients. Most AEs were mild or moderate; 33 patients 17.6% ; in the ropinirole group and 20 patients 10.4% ; in the placebo group reported at least 1 AE that was classified as severe. The only severe AEs reported in more than 2% of patients were nausea ropinirole, 15 187 [8.0%]; placebo, 1 193 [0.5%] ; and vomiting ropinirole, 4 187 [2.1%]; placebo, 1 193 [0.5%] ; . The withdrawal rate due to AEs during treatment was low and was similar between the groups ropinirole, 5 187 [2.7%]; placebo, 8 193 [4.1%] ; . All the treatment AEs leading to premature discontinuation of the study were isolated events reported by single patients. During the treatment phase, no patients in the ropinirole group reported a serious AE; there was 1 report of a serious AE chest pain ; in the placebo group. During the follow-up phase, 3 patients had reports of a serious AE; 1 patient in the ropinirole group reported 2 AEs abdominal pain and an event that was unresolved at the time of recording and coded to the Medical Dictionary for Regulatory Activities term of "ill-defined disorder" ; and 2 patients in the placebo group reported single AEs pneumonia and a traffic crash ; . One of the serious AEs in each treatment group was fatal ill-defined disorder and traffic crash both of these serious AEs occurred in the follow mayoclinicproceedings and atomoxetine.

It got the size of a golf ball and split the skin before he returned to the doctor to have him lance it. Neuroleptic malignant syndrome is a potentially fatal complication that occurs most often with typical neuroleptics but has been reported with nearly all antidopaminergic drugs. NMS has 3 major components: autonomic instability; altered mental status; and motor abnormalities. Symptoms of autonomic instability include fever; dyspnea; tachycardia; fluctuating blood pressure; pallor or flushing; and urinary incontinence. Mental status alterations range from delirium and psychosis to obtundation and coma. Motor abnormalities of NMS include hyperreflexia, rigidity, and myoclonus. Laboratory evaluations typically show elevated creatine kinase, leukocytosis, and increased iron levels. In suspected cases of NMS, the neuroleptic drug should be discontinued immediately and the patient should be monitored closely in an intensive care setting. Vigorous hydration to prevent rhabdomyolysis and external or internal cooling are also indicated. In mild cases, drug treatment consists of oral, IV, or IM benzodiazepines administered at 6-hour intervals until symptoms are controlled. There are no major contraindications to benzodiazepine therapy but they can cause sedation and respiratory depression. Bromocriptine or other dopamine agonists e.g., pergolide, pramipexole, ropinirole ; , levodopa, and amantadine are indicated for moderately severe NMS. Hypotension can occur with all of these agents and hallucinations have been reported with most. Bromocriptine has been associated with MI, stroke, and seizure. Levodopa can cause nausea. Edema and rash can occur with amantadine. Patients experiencing hypermetabolic crisis should be treated with adjunctive dantrolene. However, dantrolene is contraindicated in patients with active liver disease and its adverse and donepezil.
Patients. These results are in accordance with previous uncontrolled reports [1, 30]. Interestingly, we did not find any correlation between sleep quality scores at night and daytime somnolence or sleep attacks. This finding reinforces the notion that abnormal daytime sleepiness is not directly linked to nighttime sleep problems [31]. In order to identify potential predictors or risk factors for SA in PD patients, we compared patients who suffered from SA with those who did not. The former group had longer disease duration, longer levodopa treatment, lower levodopa dose and, as already discussed, higher ESS score. On the contrary, disease severity as measured by the UPDRS motor part `ON' ; or the Schwab and England scale, and the presence of motor complications were not different between both groups. Similarly, and in spite of previous observations [22, 32], hallucinations and orthostatic hypotension were not more frequent in PD patients with SA. In the regression explanatory model, the most consistent factor in predicting SA was the duration of levodopa treatment. However, isolated, this variable had little predictive power. In this model, the only other variable that appeared as potential key predictor was levodopa dose, lower doses being associated with a greater risk of SA. This unexpected finding is not consistent with previous reports [25, 27] and we cannot exclude a statistical bias. Nevertheless, taken together, our and other findings suggest that a single cause for SA is unlikely. Multifactor heterogeneous disease- and treatmentrelated factors are probably implicated and might vary significantly from one patient to the other. Recent case reports have raised the question that certain antiparkinsonian medications, and not others, could cause SA. The present survey did not confirm this assumption, and no drug or class of drug such as dopamine agonists as a whole ; was identified as a significant predictor factor. However two main factors limited this analysis. First, almost all patients received levodopa 87% ; which limited the inclusion of this drug in the model as an independent variable, while sedation has been reported in healthy volunteers on levodopa [33]. Secondly, of the 111 patients treated with a dopamine agonist, only two drugs were largely prescribed: 88% patients were either on the `old' ergot derivative bromocriptine 60 ; or either on the `newer' non-ergoline D2-like agonist ropinirole 46 ; . This limited the comparative analysis to these two drugs. Nevertheless, it is worth noticing that the proportion of patients with SA treated with either drug was comparable, with no greater representation of ropinirole. This finding is in line with other recent reports [29] and does not support previous concerns specifically related to the most recent agonists. The fact that pramipexole and pergolide were not marketed in France when this survey was.
Long-term maintenance of efficacy in the treatment of RLS was demonstrated in a 36-week study. Following a 24-week single-blind treatment phase flexible doses of REQUIP of 0.25 to 4 mg once daily ; , patients who were responders defined as a decrease of 6 points on the IRLS Scale total score relative to baseline ; were randomized in double-blind fashion to placebo or continuation of REQUIP for an additional 12 weeks. Relapse was defined as an increase of at least 6 points on the IRLS Scale total score to a total score of at least 15, or withdrawal due to lack of efficacy. For patients who were responders at week 24, the mean dose of ropinirole was 2 mg range 0.25 to 4 mg ; . Patients continued on REQUIP demonstrated a significantly lower relapse rate compared with patients randomized to placebo 32.6% vs 57.8%, p 0.0156 ; . INDICATIONS AND USAGE Parkinson's Disease: REQUIP is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of REQUIP was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa see CLINICAL PHARMACOLOGY: Clinical Trials ; . Restless Legs Syndrome: REQUIP is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome RLS ; . Key diagnostic criteria for RLS are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with moderate-to-severe RLS. CONTRAINDICATIONS REQUIP is contraindicated for patients known to have hypersensitivity to the product and oxcarbazepine. With 10% FCS, 50 I.U. penicillin 50 ug ml streptomycin, NEAA, and L-glutamine, as for the RAW264 cells. Human foreskin fibroblasts, originally isolated from neonatal foreskin, were grown as for mg-63 cells and used at passage 25. Primary cultures of murine calvarial osteoblasts were isolated by collagenase digestion of calvariae of neonatal mice, then grown in a-MEM, supplemented with 10% FCS, 50 I.U. penicillin 50 ug ml streptomycin, and incubated in 5% CO2 at 37C. The cells were used at passage 2. Primary ovine meniscal cells were isolated by pronase E digestion followed by collagenase digestion and were used at passage 2. Ovine articular chondrocytes had been isolated by collagenase digestion and were used at passage 2. Both ovine cultures were investigated in DMEM supplemented with 10% FCS, 50 I.U. penicillin 50 ug ml streptomycin, lx nonessential amino acids NEAA ; , and 2 mM L-glutamine, and incubated in 5% CO2 at 37C. All tissue culture media and supplements were obtained from Gibco Paisley, Scotland ; . Cell morphology and apoptosis U937 cells were set up as cell suspensions containing 2 x 105 cells ml in either serum-free conditions or in medium containing 10% FCS. Unstimulated cells displayed a "monocyte-like" phenotype, while cells of a "macrophage-like" phenotype were prepared by addition of 100 ng ml PMA. Doxycycline, CMT-2, CMT-3, and CMT-5 were prepared in Dulbecco's phosphate-buffered saline PBS; Oxoid, Basingstoke, UK ; and adjusted to pH 7.5 by titration with 1 N NaOH and 1 N HC1. The cells were treated for 24 hrs with each of these test materials at concentrations of 5, 12.5, 25, and 50 ug ml, and cytospin slides were obtained for each treatment. For cell morphology, the slides were fixed in methanol and stained with 56% v v ; Jenner's stain, followed by 25% v v ; Giemsa stain both stains obtained from Merck, Darmstadt, Germany ; . When viewed by a light microscope, the nuclei stained as dark purple and the cytoplasm as a lighter violet. Apoptosis was determined by means of the FragEL DNA fragmentation kit Amersham, UK; either the Klenow fragment of DNA polymerase or terminal transferase was used ; , following the manufacturer's instructions. Briefly, in this assay, the enzyme would bind to the 3'-OH ends of DNA fragments generated in response to apoptotic signals, thereby catalyzing the incorporation of biotinylated deoxynucleotides. The addition of diaminobenzidine to streptavidinhorseradish peroxidase conjugate generated an insoluble dark brown chromagen at the site of DNA fragmentation. When examined by a light microscope, dark brown nuclear fragments were clearly visible where apoptosis had occurred. Non-apoptotic cells were visualized with a methyl green counterstain. The numbers of apoptotic cell nuclei were assessed by means of a counting grid, and the resultant numbers of apoptotic cells were expressed as a percentage of the total cell number per grid. Counting was carried out on three separate areas of each cytospin slide 200 cells per area ; , and the arithmetic mean and standard deviation were taken. This methodology should be considered to be semiquantitative, since some subjectivity was required to assess if. Carolyn , steffi, requip ropinirole is a med i didn't take for long and disulfiram. The demand for prescription drugs is influenced by the complex structure of health insurance and health care provision. It is generally believed that the presence of health insurance makes consumers relatively insensitive to the price of health care. Although not empirically measured, this relationship is expected to apply to the demand for pharmaceuticals as well. The full impact of health insurance on prescription demand is somewhat muted by deductibles and copayments; nonetheless, health insurance almost certainly makes consumers less sensitive to drug prices. As was noted many times during the recent health care reform debate, many privately insured Americans are protected from extraordinary medical costs and, thus, have little incentive to limit health care expenditures, including the use of prescription drugs. According to OTA, in 1987, 28 percent of all prescribed drug expenditures were paid for by private insurance, 10 percent by Medicaid, 6 percent by other insurers such as Medicare and Worker's Compensation, and 57 percent by individuals.56. The quality assessment is undertaken to assess whether the pharmaceutical product being evaluated meets the requirements recommended by WHO, and is manufactured in compliance with good manufacturing practices GMP ; . The procedure established by WHO for quality assessment incorporates: general understanding of the production and quality control activities of the manufacturer; assessment of product data and information on safety, efficacy and quality submitted by the manufacturer, including product formulation, manufacture and test data and results; assessment of the manufacturing site's adherence to GMP, and its consistency in production and quality control of starting materials, with specific emphasis on active pharmaceutical ingredients, and finished product; assessment of clinical testing units or organizations i.e. parties performing one or more clinical trials with the product ; for compliance with good clinical practices and good laboratory practices, as appropriate; random sampling and testing of medicines supplied. Previous evaluation conducted by the relevant National Drug Regulatory Authority NDRA ; may be taken into account during the evaluation conducted by WHO, provided that NDRA has expertise in the product area. If appropriate, the relevant NDRA may be invited to collaborate with WHO on the quality assessment. Any manufacturer who submits a product for evaluation, is therefore encouraged to authorize its NDRA to discuss relevant product files with WHO representatives, during assessments and inspections, if required subject to appropriate confidentiality provisions, if necessary ; . Once WHO is satisfied that quality assessment has been completed for the manufacturer of the relevant starting materials, the finished pharmaceutical product, and the clinical testing units, and that the product meets WHO recommended standards, the product as produced at the specified manufacturing site ; is added to the WHO List of Prequalified Medicines and mefloquine. Chemical Agents for Dissolving Hydatid Cyst Membranes fragile. However, the effect of hypertonic saline was observed in the first few hours, and then the membrane remained stable. On day 7, the membrane integrity was preserved. A solution of hypertonic saline was found to be the most effective compared with other agents Betadine and alcohol ; used in clinical practice. Metronidazole, an antiparasitic drug, showed effects on the hydatid cyst membrane similar to the effects of hypertonic saline. Piperazine hexahydrate and levamisole induced membrane translucency. Although that is an interesting finding, we do not think that making the membrane translucent has any particular importance. One of the most commonly used agents, Betadine, showed a limited effect on the cyst membrane. Alcohol, which is used widely in clinical studies for sclerosis, and acetone did not change the integrity of the membrane but made it more rigid and fixed in form compared with the control sample. Therefore, alcohol appeared not to be suitable for dissolving the membrane. Karayalin et al. [14] reported that hypertonic 20% ; saline and absolute alcohol had no effect on daughter cysts. In their study, macroscopic examination of daughter cysts showed no change in the integrity of the wall after 1 hr of exposure to hypertonic saline and alcohol. The most remarkable result in this study was the complete dissolution of hydatid cyst membranes by sodium hypochlorite. A 2.5% solution of sodium hypochlorite melted the hydatid cyst membrane completely in the first few minutes. We then studied more diluted forms of this solution, and the most diluted form 0.1% ; caused melting of the membrane in 1 hr. Sodium hypochlorite been used in a patient with nephrolithiasis to sanitize pyogangrenous foci during renal surgery [21]. In another study, sodium hypochlorite was used during endodontic treatment of the tooth canal [22]. Also, 0.6% sodium hypochlorite was studied in cataract surgery for cleaning the lens [23]. Girardo et al. [24] showed that sodium hypochlorite has a strong antiseptic effect on gram-negative microorganisms. Another study showed similar results for Legionella species [25]. Zanini and Graeff-Teixeira [26] showed that sodium hypochlorite is effective on living larvae and can be used for food decontamination. In fact, sodium hypochlorite has been long used for water sanitation. If sodium hypochlorite is sufficiently studied and proven to be safe for host tissue, it may be a perfect agent as an adjunct to percutaneous drainage of hydatid cysts because of its antiparasitic and membrane dissolution properties. Having the potential to improve the success of percutaneous drainage, sodium hypochlorite may be able to expand the indications for percutaneous drainage of hepatic hydatid cysts. We think that further studies are needed to determine the optimal dose and possible toxic effects of this agent. In conclusion, unlike surgery, percutaneous drainage cannot extract the hydatid cyst membrane, which may reduce both the short- and long-term efficacy of percutaneous drainage. If an agent can be found that is efficacious for dissolving the hydatid cyst membrane, the effectiveness of percutaneous drainage will increase, complications will decrease, and indications for percutaneous drainage will broaden. In our in vitro study, none of the agents used in clinical practice had significant effects on hydatid cyst membranes. However, sodium hypochlorite was effective in dissolving the membranes. Because the use of this agent on living tissue is limited, further study is needed to investigate its clinical usefulness. 26 12. Smith DA, Hauser RA, Friedlander J, Malapira TJ, Nolan MF. Stimulation induced thalamic ataxia syndrome. Poster Presentation. 49th Annual Meeting of the American Academy of Neurology. Boston, MA, April 17, 1997. 13. Zesiewicz TA, Naidu KA, Baker M, Pedregal A, Prockop L, Hauser RA. Effect of amitriptyline, fluoxetine, and sertraline on dopamine concentration in rat striatum. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson's disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997. 14. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA. Evaluation of a new home diary to assess functional status in Parkinson's disease patients with fluctuations and dyskinesia. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson's disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997. 15. Hauser RA, Zesiewicz TA, Friedlander J, Seeberger LC, O'Brien CF, Adler CH, Molho ES, Factor SA. Impact of different severities of dyskinesia on patient-defined functional status in Parkinson's disease. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson's disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997. 16. Hauser RA, Anderson WMcD, Friedlander J, Zesiewicz TA, Gauger LL. Somnolence associated with pramipexole therapy in Parkinson's disease. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson's disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997. 17. Hauser RA, Stern MB, Olanow CW, Ferzola N, Azzaro A, Sharoky M. Tolerability and safety of transdermal selegiline in mild to moderate Parkinson's disease. Movement Disorders 1998; 13 Suppl 2 ; : 256. Poster Presentation. Fifth International Congress of Movement Disorders. New York, NY. October 13, 1998. 18. Wendell CM, Hauser RA, Nagaria MH, Sanchez-Ramos JR, Zesiewicz TA. Chief complaints of patients with Parkinson's disease. Platform Presentation by Hauser RA. 51st Annual Meeting of the American Academy of Neurology. Toronto, Ontario, Canada. April 20, 1999. 19. Hauser RA, Stoessl JA, Eichler SR, Schwartz SW, Sanberg PR, Saporta S, Nauert M, Randall T, Hahn MA, Scott DL, Freeman TB. Pilot evaluation of human fetal striatal transplantation in Huntington disease. Platform Presentation by Hauser RA. 52nd Annual Meeting of the American Academy of Neurology. San Diego, California. May 5, 2000. 20. Hauser RA, Wahba MN, Zesiewicz TA. Modafinil treatment of pramipexole-induced somnolence. Poster Presentation by Hauser RA. 6th International Congress of Parkinson's Disease and Movement Disorders. Barcelona, Spain. June 3, 2000. 21. Hauser RA, Reider C, Stacey M, Hubble J, Seeberger L, Gauger L, Williamson K, Dingmann C, Rice R, Krulewicz S, Zaninelli R. Acute versus gradual pramipexole to ropinirole switch. Poster Presentation by Hauser RA. 6th International Congress of Parkinson's Disease and Movement Disorders. Barcelona, Spain. June 3, 2000 and cilostazol and Buy ropinirole.

The story is long what happened to me, and very painful. Number % ; of Subjects That Experienced a Greater Than or Equal to 20%, 30% or 50% Reduction in Pain Measured by the PI-NRS score ITT Population ; Study Visit; n for PBO and ROP Percentage Reduction From Placebo Ropibirole CR Baseline in PI-NRS Score N 91 N Week 1; PBO n 87; ROP n 86 5 20% ; 6 7 ; 30% 0 0 50% Week 2; PBO n 85; ROP n 86 14 20% ; 6 7 ; 30% 1 ; 4 5 ; 50% Week 3; PBO n 83; ROP n 81 15 20% ; 9 11 ; 30% 3 4 ; 3 4 ; 50% Week 4; PBO n 81; ROP n 77 16 20% ; 11 14 ; 30% 1 ; 5 6 ; 50% Week 5; PBO n 80; ROP n 74 18 20% ; 15 20 ; 30% 3 4 ; 5 7 ; 50% Week 6; PBO n 79; ROP n 74 24 20% ; 16 22 ; 30% 4 5 ; 8 11 ; 50% Week 7; PBO n 70; ROP n 65 25 20% ; 12 18 ; 30% 4 6 ; 5 8 ; 50% Week 8; PBO n 70; ROP n 60 26 20% ; 17 28 ; 30% 6 9 ; 8 13 ; 50% Week 9; PBO n 70; ROP n 57 27 20% ; 14 25 ; 30% 9 13 ; 6 11 ; 50% Week 10; PBO n 70; ROP n 54 25 20% ; 17 31 ; 30% 11 16 ; 7 13 ; 50% Week 11; PBO n 67; ROP n 50 25 20% ; 17 34 ; 30% 10 15 ; 9 18 ; 50% Week 12; PBO n 66; ROP n 50 24 20% ; 18 36 ; 30% 11 17 ; 8 16 ; 50% Week 12 LOCF; 27 31 ; 27 31 ; 20% PBO n 87; ROP n 87 19 30% ; 9 10 ; 50% Percentages are calculated on the number of subjects n ; with a non-missing percentage reduction. The percent values do not add up to 100% as each row represents a separate cut off; PBO Placebo; ROP Dopinirole CR. A general practitioner complained about GlaxoSmithKline's involvement with the Ekbom Support Group ESG ; , a support group for patients with restless leg syndrome RLS ; . The complainant noted that GlaxoSmithKline had placed advertisements in the GP press drawing the reader's attention to RLS as a condition and advising that patients might like to know about the ESG website. The complainant understood that GlaxoSmithKline's product, ropinirole, would soon be licensed for the treatment of RLS. The complainant noted that a newsletter on the ESG website referred to the use of ropinirole for RLS in Germany and the US and alleged that GlaxoSmithKline's advertisement might thus indirectly promote the product for use in a condition for which it had no UK licence. This seemed a cynical attempt, by a company with huge financial conflicts of interest, to exploit a patient support group. The Panel noted that the advertisement in question was used from September 2004 until November 2005; it had only appeared in medical journals. GlaxoSmithKline had not informed patients or the public of the availability of the ESG website. In the UK ropinirole GlaxoSmithKline's product Requip ; was indicated for use in the treatment of Parkinson's disease. The Panel noted that the ESG newsletter, October 2005, referred to ropinirole which was only licensed for RLS in Germany and the US. The newsletter predated the advertisement. The Panel noted that the ESG website included information about approaches for helping patients with RLS including medicines. There was no product licensed in the UK for RLS but it was anticipated that ropinirole would be so licensed by April 2006. The Panel noted that it would have been a breach of the Code to include the information about the use of ropinirole in RLS in the advertisement as this would have constituted promotion of an unlicensed indication. On that basis, the Panel considered that referring health professionals to a website that included a newsletter giving information about an unlicensed indication in effect promoted that unlicensed indication. If that were not the case then companies would be able to refer to independent websites as a means of avoiding the restrictions in the Code. A breach of the Code was ruled which was appealed by GlaxoSmithKline.

Ropinirole children